Enramycin is a polypeptide antibiotic that displays strong activity against gram positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is produced by the fungus Streptomyces fungicidus as Enramycin A (EA) and Enramycin B (EB), with this product containing an approximate 70:30 ratio of EA to EB. Enramycin has been effective against antibiotic resistant bacteria by inhibiting peptidoglycan synthesis for bacterial cell walls.
Enramycin has been proposed to halt peptidoglycan synthesis by inhibiting transferase enzyme MurG or by inhibiting transglycosylase activity. Both inhibitory pathways entail enramycin binding to peptidoglycan precursors in a cell wall synthesis pathway. Some studies have shown that enramycin binds the precursor Lipid I and inhibits MurG. Enramycin has also been shown to bind the Lipid II and prevent transglycosylation of the precursor by tranglycosylases.
Antibiotics are often used in clinical in vitro tests known as antimicrobial susceptibility tests or ASTs to determine their efficacy against certain bacterial species. They are tested against gram-negative and gram-positive bacteria using panels, discs, and MIC strips by medical microbiologists. ASTs decrease the risk of using an antibiotic against bacteria exhibiting resistance to it, and the results are used in clinical settings to determine which antibiotic(s) to prescribe for various infections.
Enramycin A: C107H138Cl2N26O31
Enramycin B: C108H140Cl2N26O31
Enramycin A: 2355.30 g/mol
Enramycin B: 2369.32 g/mol
Storage/Handling: Store at -20°C.
PubChem Chemical ID: 56842192